EW Earnings

EW reported its FY2025Q4 earnings on 2026-02-10, showcasing a revenue of 0.00 against an estimate of 2.00B, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.61 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following EW's FY2025Q4 earnings announcement on 2026-02-10, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, EW's stock price tends to shift by an average of -0.70% in the 10 days leading up to earnings and -4.02% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate EW’s annual revenue to reach 2.00B, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.93% and EPS estimates Revise Downward by -0.03% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between EW's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.93%, while EPS estimates moved Revise Downward by -0.03% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EW's stock price typically moves by -0.70% in the 10 days before its earnings and -4.02% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 2.00B.

The earnings call indicates strong financial performance, with significant sales growth across key segments and raised guidance for 2025. Despite a slight decrease in profit margins, the overall outlook remains positive, supported by new product launches and strategic investments. The Q&A section highlights management's confidence in sustained growth, although some concerns about FX impacts and litigation charges were noted. The positive physician feedback and strategic initiatives further bolster the sentiment, suggesting a positive stock price movement over the next two weeks.